Rosenthal SA et al., 2019-05-10: RTOG 0521 randomised 563 evaluable men with high-risk non-metastatic prostate cancer to androgen suppression plus radiotherapy with or without six cycles of adjuvant docetaxel. Four-year overall survival was 89% vs 93% (HR 0.69, one-sided P=.034), with fewer distant metastases at six years (9.1% vs 14%).
Four-year OS rate was 89% (95% CI, 84% to 92%) for AS + RT and 93% (95% CI, 90% to 96%) for AS + RT + CT (hazard ratio [HR], 0.69; 90% CI, 0.49 to 0.97; one-sided P = .034).
Abstract (RESULTS)
Rosenthal SA et al., 2019-05-10: RTOG 0521 randomised 563 evaluable men with high-risk non-metastatic prostate cancer to androgen suppression plus radiotherapy with or without six cycles of adjuvant docetaxel. Four-year overall survival was 89% vs 93% (HR 0.69, one-sided P=.034), with fewer distant metastases at six years (9.1% vs 14%). Funder: trial run by NRG Oncology/RTOG under NCI cooperative group mechanisms; the JCO funding and disclosure appendix could not be retrieved (PMC page returned no text in this run) – verifier should pull the JCO PDF. Maker: Sanofi (docetaxel). Comparator: androgen suppression plus radiotherapy alone. This is chemotherapy added to radiotherapy, not chemotherapy alone, and the survival result rests on a one-sided test with a 90% CI. Study type: randomized trial.
